Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.
Tariff support for health IT launched in South Korea following Trump’s tariff and more briefs
The South Korean government has launched a tariff support center to assist medical device companies with trade challenges, particularly related to U.S. tariffs. Meanwhile, Johnson
